Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.

ABSTRACT:

Background

Alemtuzumab is administered as two annual courses for relapsing-remitting multiple sclerosis (MS). Patients may relapse before completing the two-course regimen.

Objective

The objective was to evaluate 6-year outcomes in patients who relapsed between alemtuzumab Courses 1 and 2 (early relapsers).

Methods

Post hoc analysis of patients from the Comparison of Alemtuzumab and Rebif^® Efficacy in Multiple Sclerosis (CARE-MS) studies who enrolled in the extension.

Results

Early relapsers (CARE-MS I: 15%; CARE-MS II: 24%) had more relapses in 1-2 years pre-alemtuzumab and higher mean baseline Expanded Disability Status Scale score than patients without relapse. Their annualized relapse rate declined from Year 1 (CARE-MS I: 1.3; CARE-MS II: 1.2) to

SUBMITTER: Van Wijmeersch B 

PROVIDER: S-EPMC7604550 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature